322 related articles for article (PubMed ID: 21523318)
1. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
Yamaguchi T; Kakefuda R; Tajima N; Sowa Y; Sakai T
Int J Oncol; 2011 Jul; 39(1):23-31. PubMed ID: 21523318
[TBL] [Abstract][Full Text] [Related]
2. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
3. Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor.
Yamaguchi T; Yoshida T; Kurachi R; Kakegawa J; Hori Y; Nanayama T; Hayakawa K; Abe H; Takagi K; Matsuzaki Y; Koyama M; Yogosawa S; Sowa Y; Yamori T; Tajima N; Sakai T
Cancer Sci; 2007 Nov; 98(11):1809-16. PubMed ID: 17784872
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
6. A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells.
Matsui TA; Murata H; Sowa Y; Sakabe T; Koto K; Horie N; Tsuji Y; Sakai T; Kubo T
Oncol Rep; 2010 Aug; 24(2):329-33. PubMed ID: 20596617
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
[TBL] [Abstract][Full Text] [Related]
11. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
12. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
13. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
Yamaguchi T; Kakefuda R; Tanimoto A; Watanabe Y; Tajima N
Inflamm Res; 2012 May; 61(5):445-54. PubMed ID: 22245957
[TBL] [Abstract][Full Text] [Related]
14. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
15. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
16. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
17. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
20. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
